A Phase 3 interventional study of Ramucirumab (IMC-1211B) DP and Placebo in Gastric Cancer, sponsored by Eli Lilly and Company. Completed at 167 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
The aim of this study is to determine if paclitaxel given together with ramucirumab (IMC-1211B) as second line therapy will prolong overall survival (OS) compared to paclitaxel alone.
Approximately 663 participants (at least 18 years) in approximately 200 study centers and in approximately 30 countries will be randomized with histologically or cytologically confirmed metastatic gastric or gastroesophageal junction adenocarcinoma. Participants must have received at least one cycle of first line therapy with any platinum/fluoropyrimidine doublet with or without anthracycline (epirubicin or doxorubicin) and must have discontinued this therapy prior to study entry due to disease progression.
Upon registration and completion of screening procedure and reviewing the Inclusion and Exclusion Criteria eligible participants will be randomized to receive either paclitaxel plus ramucirumab or paclitaxel plus placebo.
Ramucirumab (IMC-1211B) DP/placebo will be administered IV on Days 1 and 15, paclitaxel will be administered IV on Days 1, 8 and 15 of a 4 weekly cycle.
Participants will be continuously treated and monitored until radiographic or symptomatic progression of disease, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's enrollment of 665 is above the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ramucirumab (IMC-1211B) DP and Paclitaxel
Biological: Ramucirumab (IMC-1211B) DP · Drug: Paclitaxel
Placebo and Paclitaxel
Drug: Placebo · Drug: Paclitaxel
8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
Also known as: LY3009806, IMC-1211B
Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
Overall Survival Time (OS)
OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.
Time frame: Randomization up to 27.5 months
Progression-Free Survival (PFS)
PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause. PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization. Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment. Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy. Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.
Time frame: Randomization up to 22.2 months
Time to Progressive Disease (TTP)
TTP was defined as the time from randomization until date of radiographic progression using RECIST v1.1 criteria. PD was defined as having a ≥20% increase in sum of longest diameter (LD) of target lesions and at minimum 5 millimeters (mm) increase above nadir. Participants who did not progress or were lost to follow-up were censored at the date of last tumor assessment. Participants who had no baseline tumor assessment or no post baseline assessment and no death reported with 2 scan intervals post randomization were censored at date of randomization. Participants with no progression and not died within 2 scan intervals after last assessment were censored at date of last tumor assessment. Participants with no post baseline assessment or tumor progression but death reported within 2 scan intervals after randomization were censored at date of death.
Time frame: Baseline up to 22.2 months
Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD
BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir. SD was defined as small changes that did not meet above criteria.
Time frame: Randomization up to 22.2 months
Percentage of Participants With CR or PR (Objective Response Rate [ORR])
ORR was the percentage of participants who had CR or PR defined using RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. Percentage of participants calculated as: (number of participants with CR + PR)/(total number of participants)\*100.
Time frame: Randomization up to 22.2 months
Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity)
Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.
Time frame: Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks
Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion
Time frame: Cycle 1, Day 1, 1 hour post end of infusion (28-day cycles)
Cmax After 4th Ramucirumab (IMC-1211B) Infusion
Time frame: Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)
Cmax After 7th Ramucirumab (IMC-1211B) Infusion
Time frame: Cycle 4, Day 1, 1 hour post end of infusion (28-day cycles)
Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion
This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered. Cmin was not analyzed.
Time frame: Cycle 1, Day 1 predose (28-day cycles)
Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion
Time frame: Cycle 2, Day 15 (28-day cycle)
Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion
Time frame: Cycle 4, Day 1 (28-day cycles)
Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status
EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains \[physical, role, cognitive, emotional, and social\], 9 symptom scales \[fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties\] and global health status scale). 28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale. A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.
Time frame: Baseline, end of therapy (up to 103 weeks)
Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score
The EQ-5D is a generic, multidimensional, health status instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale \[1 (no problem), 2 (some problems), and 3 (major problems)\]. These combinations of responses were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.
Time frame: Baseline, end of therapy (up to 103 weeks)
Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died
Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to 103 weeks and within 30 days of last dose of study drug
| Milestone | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Started | 330 | 335 |
| Received any treatment (safety pop) | 327 | 329 |
| Completed | 316 | 315 |
| Not completed | 14 | 20 |
| Withdrew: Lost to follow-up | 3 | 9 |
| Withdrew: Withdrawal of consent without follow-up | 11 | 11 |
OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.
| months | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Overall Survival Time (OS) | 9.6 (8.5 to 10.8) | 7.4 (6.3 to 8.4) |
PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause. PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization. Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment. Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy. Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.
| months | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Progression-Free Survival (PFS) | 4.4 (4.2 to 5.3) | 2.9 (2.8 to 3.0) |
TTP was defined as the time from randomization until date of radiographic progression using RECIST v1.1 criteria. PD was defined as having a ≥20% increase in sum of longest diameter (LD) of target lesions and at minimum 5 millimeters (mm) increase above nadir. Participants who did not progress or were lost to follow-up were censored at the date of last tumor assessment. Participants who had no baseline tumor assessment or no post baseline assessment and no death reported with 2 scan intervals post randomization were censored at date of randomization. Participants with no progression and not died within 2 scan intervals after last assessment were censored at date of last tumor assessment. Participants with no post baseline assessment or tumor progression but death reported within 2 scan intervals after randomization were censored at date of death.
| months | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Time to Progressive Disease (TTP) | 5.52 (4.50 to 5.68) | 3.02 (2.86 to 4.14) |
BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir. SD was defined as small changes that did not meet above criteria.
| percentage of participants | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| CR | 0.6 | 0.3 |
| PR | 27.3 | 15.8 |
| SD | 52.1 | 47.5 |
| PD | 13.0 | 24.8 |
| Not Evaluable | 0.3 | 0.9 |
| No Tumor Response Evaluation | 6.7 | 10.7 |
ORR was the percentage of participants who had CR or PR defined using RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. Percentage of participants calculated as: (number of participants with CR + PR)/(total number of participants)\*100.
| percentage of participants | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Percentage of Participants With CR or PR (Objective Response Rate [ORR]) | 27.9 (23.3 to 33.0) | 16.1 (12.6 to 20.4) |
Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.
| percentage of participants | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity) | 1.6 | 0.3 |
| micrograms/milliliter (µg/mL) | Ramucirumab (IMC-1211B) Plus Paclitaxel |
|---|---|
| Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion | 146 ± 28 |
| µg/mL | Ramucirumab (IMC-1211B) Plus Paclitaxel |
|---|---|
| Cmax After 4th Ramucirumab (IMC-1211B) Infusion | 193 ± 34 |
| µg/mL | Ramucirumab (IMC-1211B) Plus Paclitaxel |
|---|---|
| Cmax After 7th Ramucirumab (IMC-1211B) Infusion | 216 ± 30 |
This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered. Cmin was not analyzed.
No measurements were reported for this outcome.
| µg/mL | Ramucirumab (IMC-1211B) Plus Paclitaxel |
|---|---|
| Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion | 45.0 ± 50 |
| µg/mL | Ramucirumab (IMC-1211B) Plus Paclitaxel |
|---|---|
| Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion | 62.8 ± 47 |
EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains \[physical, role, cognitive, emotional, and social\], 9 symptom scales \[fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties\] and global health status scale). 28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale. A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.
| units on a scale | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status | -13.5 ± 23.24 | -12.1 ± 24.81 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale \[1 (no problem), 2 (some problems), and 3 (major problems)\]. These combinations of responses were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.
| units on a scale | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score | -0.16 ± 0.279 | -0.19 ± 0.337 |
Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel |
|---|---|---|
| SAEs | 161 | 146 |
| Other Non-serious AEs | 324 | 321 |
| Died | 37 | 52 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab and Paclitaxel | — | 161/327 (49.2%) | 324/327 (99.1%) |
| Placebo and Paclitaxel | — | 146/329 (44.4%) | 321/329 (97.6%) |
| Event | Ramucirumab and Paclitaxel | Placebo and Paclitaxel |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 48/327 | 49/329 |
| NeutropeniaBlood and lymphatic system disorders | 12/327 | 4/329 |
| Abdominal painGastrointestinal disorders | 10/327 | 11/329 |
| VomitingGastrointestinal disorders | 7/327 | 10/329 |
| General physical health deteriorationGeneral disorders | 8/327 | 9/329 |
| AnaemiaBlood and lymphatic system disorders | 8/327 | 7/329 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/327 | 5/329 |
| PyrexiaGeneral disorders | 8/327 | 7/329 |
| FatigueGeneral disorders | 5/327 | 7/329 |
| Intestinal obstructionGastrointestinal disorders | 6/327 | 3/329 |
| Event | Ramucirumab and Paclitaxel | Placebo and Paclitaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 174/327 | 102/329 |
| Decreased appetiteMetabolism and nutrition disorders | 131/327 | 105/329 |
| FatigueGeneral disorders | 128/327 | 104/329 |
| AlopeciaSkin and subcutaneous tissue disorders | 107/327 | 127/329 |
| AnaemiaBlood and lymphatic system disorders | 110/327 | 116/329 |
| NauseaGastrointestinal disorders | 114/327 | 106/329 |
| LeukopeniaBlood and lymphatic system disorders | 111/327 | 69/329 |
| DiarrhoeaGastrointestinal disorders | 105/327 | 76/329 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 100/327 | 23/329 |
| Abdominal painGastrointestinal disorders | 98/327 | 62/329 |
All randomized participants.
| Age, Categorical(Participants) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 205 | 213 | 418 |
| >=65 years | 125 | 122 | 247 |
| Age, Continuous(years) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| Median | 61 (25 to 83) | 61 (24 to 84) | 61 (24 to 84) |
| Sex: Female, Male(Participants) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| Female | 101 | 92 | 193 |
| Male | 229 | 243 | 472 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 26 | 57 |
| Not Hispanic or Latino | 299 | 309 | 608 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 110 | 121 | 231 |
| Black or African American | 6 | 6 | 12 |
| White | 208 | 199 | 407 |
| More than one race | 0 | 1 | 1 |
| Other | 6 | 7 | 13 |
| Region of Enrollment(Participants) | Ramucirumab (IMC-1211B) Plus Paclitaxel | Placebo Plus Paclitaxel | Total |
|---|---|---|---|
| Portugal | 2 | 0 | 2 |
| United States | 12 | 12 | 24 |
| Estonia | 5 | 5 | 10 |
| Taiwan | 14 | 16 | 30 |
| Spain | 8 | 13 | 21 |
| Russia | 8 | 13 | 21 |
| Chile | 1 | 3 | 4 |
| Italy | 13 | 15 | 28 |
| France | 20 | 14 | 34 |
| Australia | 18 | 23 | 41 |
| South Korea | 23 | 22 | 45 |
| Lithuania | 6 | 6 | 12 |
| Austria | 4 | 2 | 6 |
| United Kingdom | 6 | 9 | 15 |
| Hungary | 20 | 9 | 29 |
| Mexico | 2 | 2 | 4 |
| Argentina | 1 | 0 | 1 |
| Poland | 15 | 18 | 33 |
| Brazil | 19 | 16 | 35 |
| Belgium | 12 | 14 | 26 |
| Singapore | 2 | 3 | 5 |
| Romania | 7 | 7 | 14 |
| Bulgaria | 7 | 5 | 12 |
| Germany | 20 | 20 | 40 |
| Japan | 68 | 72 | 140 |
| Hong Kong | 2 | 1 | 3 |
| Israel | 15 | 15 | 30 |
Showing the first 100 of 167 sites across 26 countries.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company